Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
September 23, 2023 at 15:19 PM EDT
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make an upfront payment of $7 million to Kezar.
